25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Mystic Asset Management Inc.

Mystic Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 25,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,181,000.

Several other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $434,871,000. Rubric Capital Management LP purchased a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $21,908,000. Assenagon Asset Management S.A. acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter worth $27,428,000. Woodline Partners LP increased its position in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after acquiring an additional 490,835 shares in the last quarter. Finally, Rice Hall James & Associates LLC purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $22,800,000.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $47.45 on Friday. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68. The firm’s 50-day moving average is $46.72 and its 200-day moving average is $48.85. The company has a market cap of $2.76 billion, a P/E ratio of -24.71, a PEG ratio of 0.89 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The business had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. Supernus Pharmaceuticals’s quarterly revenue was up 32.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.40 EPS. As a group, sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.